title: Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia.
authors.forename: Parameswaran
authors.initials: P
authors.lastname: Anoop
authors.forename: Miles
authors.initials: M
authors.lastname: Stanford
authors.forename: Radovan
authors.initials: R
authors.lastname: Saso
authors.forename: Claire E
authors.initials: CE
authors.lastname: Dearden
mesh_terms: D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology; D015821:Eye Infections, Fungal / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000382:microbiology*; D008279:Magnetic Resonance Imaging; D008297:Male; D020953:Neuroaspergillosis / Q000150:complications* / Q000175:diagnosis; D009503:Neutropenia / Q000139:chemically induced / Q000382:microbiology; D011239:Prednisolone / Q000627:therapeutic use*; D012160:Retina / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D011239:Prednisolone